New publication: PBPK analysis supports dose selection for a sustained-release 5-FC for improved CM treatment in HIV patients

The publication focuses on a novel treatment for Cryptococcal meningoencephalitis (CM), a leading cause of death among people living with HIV in sub-Saharan Africa. Current treatment with 5-flucytosine (5-FC) poses significant challenges due to its short half-life and complicated dosing schedule, risking patient compliance.